With over 20,000 rigorously validated antibodies for cancer and biomedical research, NeoBiotechnologies gives you direct access to the science.
NeoBiotechnologies is a scientist-led company established in 2013 that develops highly specific, rigorously validated mAbs (monoclonal antibodies).
These empower cancer researchers, pathologists, and scientists across disciplines to achieve more accurate and insightful results. Each antibody undergoes multiple validation steps, including HuProt™ Protein Array testing against 21,000 full-length human proteins.
As a monoclonal antibodies manufacturer, we control every aspect of development and validation, ensuring reliability and deep technical expertise.
Our commitment to innovation, partnership, and scientific excellence places us at the forefront of immuno-oncology research and the future of precision medicine.
Secure uncompromised quality and complete traceability by sourcing from the manufacturer, not a reseller.
Drive your research forward with extensively tested products you can rely on for reproducible data.
Resolve technical challenges by speaking directly with the scientists who manufactured and validated the antibodies.
Keep your projects on schedule with reliable same-day or next-day dispatch to minimize downtime.
Scale your work seamlessly with tailored volumes and custom configurations designed around your workflow.
Accelerate your path to market with clear, comprehensive licensing agreements for commercialization.
Human protein arrays validate antibodies for specificity and reliability.
Rabbit monoclonal antibodies are effective for immunohistochemistry applications.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time
